TheraRadar
← Back
Data updated: Jun 28, 2026

HERITAGE PHARMA AVET

Generics

HERITAGE PHARMA AVET is a generic drug manufacturer focused on Gastroenterology, Infectious Disease.

1983
Since
15
Drugs
-
Trials
0
New Drugs (2yr)

HERITAGE PHARMA AVET's Key Drugs

HERITAGE PHARMA AVET's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

HERITAGE PHARMA AVET's Recent FDA Approvals

New NDA/BLA approvals for HERITAGE PHARMA AVET over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

HERITAGE PHARMA AVET's Therapeutic Areas

HERITAGE PHARMA AVET's approved drugs and pipeline span 2 therapeutic areas, led by Gastroenterology and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Gastroenterology 50%
1 drugs
Infectious Disease 50%
1 drugs

HERITAGE PHARMA AVET's Top Competitors

HERITAGE PHARMA AVET's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

HERITAGE PHARMA AVET Pipeline Snapshot

Active clinical trials for HERITAGE PHARMA AVET across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Gastroenterology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling